Dividend Information About IDT B: Everything You Need to Know Before Its Ex-Dividend Date on Sep 30, 2025
Generated by AI AgentAinvest Dividend Digest
Friday, Sep 26, 2025 8:01 pm ET1min read
IDT--
Aime Summary
IDT B has announced a quarterly cash dividend of $0.06 per share, with an ex-dividend date set for Sep 30, 2025. The announcement was made on Sep 22, 2025, and the dividend will be distributed on Oct 10, 2025. This payout is consistent with the company’s most recent dividend on Jun 18, 2025, which also stood at $0.06 per share. However, the current dividend is notably lower than the average of the last 10 dividend payments, which amounts to approximately $0.191 per share. Investors should note that the ex-dividend date marks the final day for shareholders to purchase the stock and still qualify for the dividend. Any purchase made after this date will not entitle the investor to this distribution.
Over the past week, IDT BIDT-- has seen several key developments influencing its market performance. Recently, the stock's 15-minute chart triggered a KDJ Golden Cross and a Bullish Marubozu on Sep 26, 2025 at 12:30 PM, signaling a potential shift in momentum toward the bullish side. Additionally, on Sep 24, 2025 at 09:30 AM, IDTIDT-- B's RSI reached an oversold level, paired with a Bullish Marubozu candle, further supporting the possibility of a short-term price rebound. Meanwhile, IDT Corp also announced its quarterly cash dividend of $0.06 per share, aligning with the company's previous payout and reiterating its commitment to consistent dividend policy. These technical and fundamental signals, combined with the recent dividend declaration, have drawn significant attention from market participants.
Since the last update, IDT B has experienced a notable decline in its stock price. On the most recent trading day, the stock closed at $62.48, marking a drop of $3.55, or 5.37%. This decline has brought the stock close to its lowest closing level since Aug 21, 2025, when it closed at $62.28. Despite this downward movement, some analysts have maintained a "Strong Buy" rating for IDT, citing a 12-month target price of $85.60, which implies a potential upside of over 25%. The stock's fundamentals remain underpinned by a stable dividend policy and recent advancements in its core business, including the launch of a new Enhancer Protein by Integrated DNA Technologies to accelerate CRISPR-based therapies.
In summary, IDT B remains a focal point for investors due to its consistent dividend yield and recent technical and fundamental developments. While the stock has faced short-term volatility, the company’s ongoing innovation and financial stability provide a strong foundation for future growth. Investors should be mindful that the ex-dividend date is set for Sep 30, 2025, and any purchase after this date will not qualify for the upcoming dividend.
Over the past week, IDT BIDT-- has seen several key developments influencing its market performance. Recently, the stock's 15-minute chart triggered a KDJ Golden Cross and a Bullish Marubozu on Sep 26, 2025 at 12:30 PM, signaling a potential shift in momentum toward the bullish side. Additionally, on Sep 24, 2025 at 09:30 AM, IDTIDT-- B's RSI reached an oversold level, paired with a Bullish Marubozu candle, further supporting the possibility of a short-term price rebound. Meanwhile, IDT Corp also announced its quarterly cash dividend of $0.06 per share, aligning with the company's previous payout and reiterating its commitment to consistent dividend policy. These technical and fundamental signals, combined with the recent dividend declaration, have drawn significant attention from market participants.
Since the last update, IDT B has experienced a notable decline in its stock price. On the most recent trading day, the stock closed at $62.48, marking a drop of $3.55, or 5.37%. This decline has brought the stock close to its lowest closing level since Aug 21, 2025, when it closed at $62.28. Despite this downward movement, some analysts have maintained a "Strong Buy" rating for IDT, citing a 12-month target price of $85.60, which implies a potential upside of over 25%. The stock's fundamentals remain underpinned by a stable dividend policy and recent advancements in its core business, including the launch of a new Enhancer Protein by Integrated DNA Technologies to accelerate CRISPR-based therapies.
In summary, IDT B remains a focal point for investors due to its consistent dividend yield and recent technical and fundamental developments. While the stock has faced short-term volatility, the company’s ongoing innovation and financial stability provide a strong foundation for future growth. Investors should be mindful that the ex-dividend date is set for Sep 30, 2025, and any purchase after this date will not qualify for the upcoming dividend.

Sip from the stream of US stock dividends. Your income play.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet